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Abstract
Background: Mutations in a novel gene, UBIAD1, were recently found to cause the autosomal dominant eye disease
Schnyder corneal dystrophy (SCD). SCD is characterized by an abnormal deposition of cholesterol and phospholipids in the
cornea resulting in progressive corneal opacification and visual loss. We characterized lesions in the UBIAD1 gene in new
SCD families and examined protein homology, localization, and structure.
Methodology/Principal Findings: We characterized five novel mutations in the UBIAD1 gene in ten SCD families, including a
first SCD family of Native American ethnicity. Examination of protein homology revealed that SCD altered amino acids which
were highly conserved across species. Cell lines were established from patients including keratocytes obtained after corneal
transplant surgery and lymphoblastoid cell lines from Epstein-Barr virus immortalized peripheral blood mononuclear cells.
These were used to determine the subcellular localization of mutant and wild type protein, and to examine cholesterol
metabolite ratios. Immunohistochemistry using antibodies specific for UBIAD1 protein in keratocytes revealed that both
wild type and N102S protein were localized sub-cellularly to mitochondria. Analysis of cholesterol metabolites in patient cell
line extracts showed no significant alteration in the presence of mutant protein indicating a potentially novel function of
the UBIAD1 protein in cholesterol biochemistry. Molecular modeling was used to develop a model of human UBIAD1
protein in a membrane and revealed potentially critical roles for amino acids mutated in SCD. Potential primary and
secondary substrate binding sites were identified and docking simulations indicated likely substrates including prenyl and
phenolic molecules.
Conclusions/Significance: Accumulating evidence from the SCD familial mutation spectrum, protein homology across
species, and molecular modeling suggest that protein function is likely down-regulated by SCD mutations. Mitochondrial
UBIAD1 protein appears to have a highly conserved function that, at least in humans, is involved in cholesterol metabolism
in a novel manner.
Citation: Nickerson ML, Kostiha BN, Brandt W, Fredericks W, Xu K-P, et al. (2010) UBIAD1 Mutation Alters a Mitochondrial Prenyltransferase to Cause Schnyder
Corneal Dystrophy. PLoS ONE 5(5): e10760. doi:10.1371/journal.pone.0010760
Editor: Mel B. Feany, Brigham and Women’s Hospital, Harvard Medical School, United States of America
Received November 9, 2009; Accepted March 3, 2010; Published May 21, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported in part by a grant from the National Eye Institute (grant EY12972 to J.S.W.) and by funding from the Eye Bank Association of
America (JSW), and the Midwest Eye Banks (J.S.W. and K.-P.X.). This project has been funded in part with federal funds from the National Cancer Institute, National
Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department
of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nickersonml@mail.nih.gov (MLN); jweiss@med.wayne.edu (JSW)
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10760Introduction
Schnyder corneal dystrophy [SCD, MIM 121800] [1,2] is an
autosomal dominant eye disease characterized by an abnormal
deposition of cholesterol and phospholipids in the cornea [3,4].
The resultant bilateral corneal opacification is progressive.
Approximately 50% of SCD patients have corneal crystalline
deposits [5] which represent cholesterol crystals. Of great interest,
two-thirds of affected individuals are hypercholesterolemic [4].
Unaffected individuals in SCD pedigrees may also demonstrate
hypercholesterolemia, thus it has been postulated that the corneal
disease results from a local metabolic defect of cholesterol
processing or transport in the cornea.
A review of 115 affected individuals from 34 SCD families
identified by one of the authors (JSW) since 1989, confirmed the
finding that the corneal opacification progressed in a predictable
pattern dependent on age [5,6]. All patients demonstrated corneal
crystals or haze, or a combination of both findings. While patients
have been diagnosed as young as 17 months of age, the diagnosis
may be more challenging if crystalline deposits are absent. In
acrystalline disease, onset of visible corneal changes may be
delayed into the fourth decade [7]. Although many patients
maintained surprisingly good visual acuity until middle age,
complaints of glare and loss of visual acuity were prominent and
increased with age. Disproportionate loss of photopic vision as
compared to scotopic vision was postulated to be caused by light
scattering by the corneal lipid deposits. Surgical removal of the
opacified cornea was reported in 20 of 37 (54%) patients 50 years
of age and 10 of 13 (77%) of patients 70 years of age [5].
Recently, several groups described the identification of
mutations in human SCD patients in a gene with no prior
connection to corneal dystrophies or cholesterol metabolism [8–
12]. The gene, UBIAD1 (italics is used to indicate the gene), is
predicted to encode a membrane protein containing a prenyl-
transferase domain similar to a bacterial (E. coli) protein, UbiA.
The human gene, UbiA prenyl-transferase Domain containing 1
(UBIAD1), spans 22 kb and the locus gives rise to approximately
three different transcripts with up to five unique exons [9]. To
date, mutations have been described exclusively in exons 1 and 2,
which encode a discrete transcript. Thirty-one apparently
unrelated families have been examined and fifteen different
mutations have been characterized. Genetic analysis of families
revealed a putative mutation hotspot that altered an asparagine at
position 102 to a serine reside [11]. Cumulatively, 12/31 (39%) of
apparently unrelated families possess this single hotspot alteration.
Thus, a major unresolved issue is whether all mutations have
similar effect and whether protein activity is up- or down regulated
by familial mutations.
The current study examined newly recruited SCD families in
order to investigate critical aspects of UBIAD1 protein structure
and function. Protein homology across species and conservation of
residues mutated in SCD were analyzed. The subcellular
localization of UBIAD1 was determined and several forms of
cholesterol were quantitated in immortalized peripheral blood
mononuclear cell lines derived from SCD patients. Finally, protein
threading was utilized to construct a three dimensional model of
membrane-bound UBIAD1. The model allowed functional
consequences of SCD mutations to be assessed and likely
substrates identified that may offer novel therapeutic approaches.
Results
Demographics of New SCD Families
Ten affected probands with SCD from ten different families
were recruited. Six families resided in the United States, Families
AA, GG, II, KK, LL, and MM. Four families resided out of the
United States: Family CC from Japan, EE from Taiwan, N from
Germany, and F1 from Finland. Clinical features of Family N
were previously published [13]. No known history of SCD was
discovered in five families, EE, GG, II, KK and LL. There was a
known family history of SCD in the remaining five families and in
three of these families (AA, F1, N) more than one affected
individual participated in our study. Affected patients demonstrat-
ed findings of SCD including superficial corneal crystals
(Figure 1A, top). This study includes a first report of SCD in a
family of Native American ancestry and the 69 year old proband
demonstrated diffuse cornea haze with scattered superficial crystals
and peripheral arcus lipoides (Figure 1B). Probands from other
families had similar corneal findings (Figure 1C and 1D).
Figure 1. Corneas and UBIAD1 gene sequencing of SCD probands. Corneal photos (top) and patient sequence chromatograms (bottom) are
shown above a wild type sequence. (A) Proband from family GG with a novel A97T mutation. External photograph of the cornea demonstrating
central and paracentral crystalline deposition in a 36 year old male. (B) Proband from family AA with a novel V122E mutation. The cornea shows
central and paracentral crystalline deposits, diffuse corneal haze, and arcus lipoides in a 69 year old male (top). (C) Proband from family KK with a
N102S mutation. The cornea shows central crystalline deposit, mid peripheral haze, and arcus lipoides in a 61 year old male. (D) Proband from family
LL with a novel D112N mutation. The cornea shows paracentral crystalline deposition in a 25 year old male.
doi:10.1371/journal.pone.0010760.g001
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Genetic analyses of the UBIAD1 gene in both new and
previously published SCD families are shown with family
ethnicities in Table 1 [7–11]. Figure 1A–1D (bottom) shows
proband sequencing in UBIAD1 for Families GG, AA, KK, and
LL. Five families exhibited novel mutations, A97T (Family GG),
D112N (LL), V122E (AA), V122G (F1), and L188H (EE). Five
newly analyzed families possessed the same N102S mutation:
Families CC, II, KK, MM, and N. Mutations of the N102 residue
are shown as distinct in Table 1 but it should be noted that some
families may be distantly related and share an N102S mutation
due to a founder effect. Over 220 chromosomes from unrelated
CEPH individuals were sequenced and examined at the site of
each novel mutation. No alterations were found in these healthy
individuals confirming that these mutations are likely associated
with SCD and not rare polymorphisms.
A phenotype-genotype discrepancy was noted in Family F1
where a patient was diagnosed as affected by corneal exam but did
not possess a V122G mutation. This may be due to difficulties of
making the diagnosis of SCD in some patients and/or families [9].
The family and mutation are included in this study as evidence
strongly suggests this is a valid SCD alteration. This includes that
fact that the same residue was mutated (V122E) in the Family AA
proband but not his unaffected sister. Examination of DNA from
over 110 healthy individuals failed to indicate the presence of rare
polymorphism(s) at this codon.
Highly Conserved UBIAD1 Residues are Mutated in SCD
The entire protein sequence was examined across species, with a
focus on residues mutated in SCD because mutation of conserved
residues could suggest interruption of an ancient function. A
previous analysis, examined homology across 23 amino acids of a
putative prenyltransferase active site [11,14]. UBIAD1 homologs
were identified in 19 species and protein sequences were aligned
using ClustalX [15] (Figure 2) Homology was high among
mammals based upon pairwise alignment scores. Compared to
human, chimp was 99.7% similar, mouse 92%, rat (92%), cattle
(91%), and dog (89%). The protein was generally conserved in
non-mammalian vertebrates. Compared to human, similarity to
chicken was 81.7%, zebrafish 78.9%, and fruitfly 59.6%.
Locations of 17 amino acids mutated in SCD are indicated
(Figure 2A, 2B). Fifteen out of 17 (88%) were universally conserved
in all 19 organisms examined from sea urchins to humans,
including A97, D112, V122, L188. Groups of SCD mutations
were clustered in regions of protein exhibiting the highest degree
of conservation between species. These were separated by regions
of protein that are less conserved. Based upon the alignment, a
phylogenic tree was created (Figure 2C). The tree is consistent with
the high conservation of the protein in mammalian species and
lesser but substantial conservation in other vertebrates.
Linear and 2D Protein Models
A linear diagram and 2-D model of UBIAD1 in a lipid
membrane (Figures 3A and 3B) demonstrate the number and
location of newly reported and previously published familial SCD
mutations [8–12]. Family GG possessed the most N-terminal SCD
alteration yet described, A97T. N102S, the site of 17 familial
mutations (41% of families), is located at the first transmembrane
spanning region. The mutated amino acids (Figure 3B) occur in
regions of the protein on one side of the membrane (Loops 1–3).
Loop 1 of the protein is affected by 9/10 of these newly reported
mutations. Other mutations described in this study, D112N and
two alterations at V122 (V122E and V122G), appear to affect
aqueous portions of Loop 1. The single Loop 2 mutation is L188H
which extends this cluster of mutations towards the C-terminus.
Localization of UBIAD1 to Mitochondria in Keratocytes
To examine whether SCD mutations altered UBIAD1 protein
trafficking, the subcellular localization of wild type and mutant
human UBIAD1 was examined (Figure 4). Localization within
cultured normal human keratocytes of UBIAD1 and protein
disulfide isomerase, an enzyme marker for the endoplasmic
reticulum, is shown (Figure 4A–4C). Co-localization of UBIAD1
and a subunit of OXPHOS complex I (NADH dehydrogenase), an
enzyme in mitochondria, is shown in Figure 4D–F. UBIAD1 did
not co-localize with the endoplasmic reticulum (Figure 4C), but
did co-localize with mitochondria (orange in Figure 4F). Figure 5
presents localization of UBIAD1 in SCD and normal keratocytes.
Co-localization of SCD mutant UBIAD1 protein and OXPHOS
complex I mitochondrial marker in disease keratocytes (Figure 5A–
5C) and normal human keratocytes (Figure 5D–F) is shown.
Analysis of Cholesterol in SCD Patients
Mutation of UBIAD1 in SCD is thought to result in deregulation
of cholesterol and lipid metabolism, resulting in an abnormal
accumulation of these substances in the cornea leading to corneal
opacification and visual loss [5]. No significant differences were
observed in total cholesterol, cholesteryl ester, and unesterified
cholesterol in SCD and healthy patient B cell lines (Table 2).
Protein Threading Model of UBIAD1 Protein
To examine UBIAD1 structure-function relationships and
assess the potential impact of SCD mutations, three dimensional
(3D) modeling was performed using protein threading. Available
X-ray structures of prenyl-converting enzymes were examined,
including a recently developed model of the all-alpha-helical E. coli
UbiA [16–19]. Modeling using the Molecular Operating Envi-
ronment (MOE) indicated UbiA but not other proteins possessed
an arrangement of alpha helical structural elements that could be
superimposed on UBIAD1 (Figure 6A). The positional placement
of geranylpyrophosphate and a single magnesium cation were
extracted from the E. coli UbiA model and fitted into the model of
UBIAD1. A second magnesium cation was manually added to the
model due to an additional aspartate close to the putative binding
site of the pyrophosphate moiety in UBIAD1.
PROCHECK assessment of stereochemical quality of the
model obtained from MOE and refined using YASARA indicated
that 86.7% of all amino acid residues were located in the most
favored area and only three residues were in disallowed (uncertain)
loop regions. All parameters evaluated were better (overall G-
factor) than similar values for an analogous X-ray crystal structure
at a 2 A ˚ resolution. Inspection of the fold quality revealed a quality
indication of 94%, with low quality scores in only five small
regions. Over 30 models were generated and evaluated to obtain
the model shown in Figure 6B and 6C. Transmembrane helices
created an approximate circular pattern to form a substrate
binding cleft on one side of the membrane. The N102 residue
occupied a position where the first TM helix exited the membrane
and its sidechain pointed inwards towards the center of a putative
prenyldiphosphate binding pocket (Figure 6C). A docked farne-
syldiphosphate is shown with magnesium cations in the active site.
The prenyl substrate appeared to approach the active site
containing N102 from the central cavity.
The model allowed docking of potential ligand(s)/substrate(s) to
be examined including those involved in reactions catalyzed by
UbiA (Figure S1) [16,17]. Database searches revealed homology
between the binding site in the model and 1,4-dihydroxy-2-
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a
Family Ethnicity
b Gene mutation
c Protein
d Exon Loop
e Publication
GG Irish-French Canadian 623 G.A A97T 1 1 this report
F123 Italian 639 A.G N102S 1 1 7
BB1 British 639 A.G N102S 1 1 8
BB2 British 639 A.G N102S 1 1 8
Q American 639 A.G N102S 1 1 8
U American 639 A.G N102S 1 1 8
Y German 639 A.G N102S 1 1 8
1 Irish 639 A.G N102S 1 1 10
BB Czechoslavakian 639 A.G N102S 1 1 9
DD Chinese-Taiwan 639 A.G N102S 1 1 9
K German 639 A.G N102S 1 1 9
L American 639 A.G N102S 1 1 9
R American 639 A.G N102S 1 1 9
CC Japan 639 A.G N102S 1 1 this report
II American 639 A.G N102S 1 1 this report
KK American 639 A.G N102S 1 1 this report
MM American 639 A.G N102S 1 1 this report
N German 639 A.G N102S 1 1 this report
h
LL French-British-CA
f 668 G.A D112N 1 1 this report
F122 Indian 669 A.G D112G 1 1 7
H American 687 A.G D118G 1 1 9
F105 Spanish?-Canadian 689 A.G R119G 1 1 7
3 African-American 689 A.G R119G 1 1 10
2 Egyptian 695 C.G L121V 1 1 10
BB3 British 695 C.T L121F 1 1 9
O American 695 C.T L121F 1 1 9
AA Native American 999 T.A V122E 1 1 this report
F1 Finnish 999 T.G V122G 1 1 this report
K1 German 845 T.C S171P 1 2 9
Case 1 Japanese 855 A.G
g Y174C 1 2 11
F115 Scottish 858 C.T T175I 1 2 7
J Hungarian-American 858 C.T T175I 1 2 9
T American 863 G.C G177R 1 2 8
X Chinese-Taiwan 863 G.A G177R 1 2 9
Z Kosovar 863 G.A G177R 1 2 9
Case 4 Japanese 876 A.G
g K181R 2 2 11
G German-American 890 G.A G186R 2 2 9
EE Chinese-Taiwan 897 T.A L188H 2 2 this report
F118 Canadian 1029 A.G N232S 2 3 7
Case 6 Japanese 1031 A.C
g N233H 2 3 11
FF African-American 1042 C.G D236E 2 3 9
aDescending order 59 to 39 nucleotide number in the Reference Sequence.
bEthnicity is given if known, otherwise location of proband is listed.
cLocation of mutation in RefSeq NM_013319.2.
dPredicted effect of genetic mutation on protein NP_037451.
eLoop, see Figure 3B.
fCA, Canadian Native American.
gNucleotides re-numbered based upon updated RefSeq NM_013319.2.
hClinical description of family N originally described in [14].
doi:10.1371/journal.pone.0010760.t001
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suggested that similar to aromatic prenyltransferases a second
(aromatic?) substrate may be involved in catalysis, e.g. 4-
hydroxybenzoate (cf. UbiA) or a 1,4-dihydroxy-naphthaline
derivative. For the latter case, bacterial menaquinone (vitamin
K-2) is the product of a similar prenylation reaction, a
Figure 2. Highly conserved UBIAD1 residues are mutated in SCD. (A) Locations of 17 amino acids mutated in SCD patients are indicated by
arrows. Taller bars in the graph below the alignment indicate greater conservation. (B) Regions of alignment encompassing human SCD mutations:
A97, D112, V122, L188, are shown. The position of the human protein in the alignment is indicated on the left (box). (C) Evolutionary relationships
based upon UBIAD1 homology.
doi:10.1371/journal.pone.0010760.g002
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naphthohydroquinone. This molecule is structurally similar to 1,4-
dihydroxy-2-naphthoate. Speculative second substrates 4-hydro-
xybenzoic acid and 1,4-naphthalin-diol were successfully docked
into the putative active site of the model (Figure S2). A tertiary
model showed naphthalinediol docked preferentially in the central
cavity in close proximity to amino acid, N102.
Docking simulations were compared using models of wild type
and SCD mutant (N102S) UBIAD1 protein and substrates,
farnesyldiphosphate and a 1,4-dihydroxy aryl compound
(Figure 6D and 6E). The diphosphate binding site was identified
in the putative active site of both models in close proximity to N102.
In the wild type protein, N102 formed weak hydrogen bonds to the
1,4-dihydroxy aryl compound (dotted line) which were lost upon
mutationtoaserineresidue.Lastly,substratedockingwasexamined
using prenylated aromatics with a role in human metabolism. This
showed that menaquinone (vitamin K) fits excellently into the
substrate binding cleft of UBIAD1 models (Figure 6F). While this
class of molecules is not a likely substrate for UBIAD1, they may be
ligands that are transferred to protein binding partners.
Amino acids mutated in SCD were found in the vicinity of the
active site, including A97, N102, D112, V122, and L188.
Figure 7A, 7B, S2, and S3 show side and top views, respectively.
The N102 residue is shown as a spacefill atom with a docked
farnesyldiphosphate. Significantly, a previously described poly-
morphism, S75F [8,9], was not identified as functionally important
to substrate docking or catalysis.
Discussion
Recruitment and analysis of new families with SCD continues to
facilitate investigation of the genotypic spectrum of this disease. Of
ten new families recruited for this study, five possessed novel
UBIAD1 alterations. SCD mutations A97T (Family GG), V122E
(Family AA), and V122G (Family F1) expand the size of the Loop
1 mutation cluster (Figure 3B). Similarly, L188H (Family EE)
expands the Loop 2 cluster. All five of the novel amino acid
substitutions represent non-conservative changes that are consis-
tent with previously described alterations (Table 1): A97T
(nonpolar to polar), D112N (negative to neutral), V122E (nonpolar
Figure 3. Locations of familial SCD alterations in UBIAD1. (A) A linear diagram of the UBIAD1 protein with independent familial mutations
(arrows). Novel familial mutations presented in this study are indicated by green arrows. Previously published SCD mutations are indicated (black
arrows). Predicted transmembrane (grey boxes) and prenyltransferase domains (horizontal line, bottom) are indicated. A previously described S75F
SNP is indicated (red arrow). Adapted from Ref. 11. (B) Locations of SCD mutations in a proposed 2-D model of UBIAD1 in a lipid bilayer. Solid Black:
SCD mutations, Orange: amino acids outside the prenyltransferase domain, Blue: acidic residues, Red: basic residues, HRM: heme regulatory motif
(box), CxxC: oxidoreductase motif (CAAC, small circle), Green: S75F polymorphism.
doi:10.1371/journal.pone.0010760.g003
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(nonpolar to polar-positive).
Three distinct lines of evidence indicate that SCD results from
loss of function of UBIAD1 protein due to a mutation: genetics,
experimental mutagenesis of UbiA, and modeling of substrate-
UBIAD1 interactions. There are three cases (Table 1) where
UBIAD1 amino acids were mutated to other residues in SCD
families, aspartic acid 112 to an asparagine or a glycine, leucine
121 to a valine or a phenylalanine, and valine 122 to a glutamic
acid or a glycine. There were significant chemical differences
between resulting mutant amino acids and from wild type. For
example, substitution of non-polar valine 122 with either polar,
negative glutamic acid or non-polar, neutral glycine results in
SCD. This suggests that loss of valine 122 may be necessary for the
formation of SCD rather than a gain of function.
Despite low overall homology between E. coli UbiA and human
UBIAD1 proteins, comparison of individual amino acids aligned
in Figure 6A suggest SCD mutations may result in loss of function
of UBIAD1. In prior work on UbiA [16–18,20], five aspartic acid
residues were judged as crucial for catalytic activity based on
modeling. These were individually mutated and all five inhibited
product formation by .95%. Figure 6A shows that mutagenized
UbiA residues (R137 and D191) aligned with amino acids in
UBIAD1 that are mutated in human SCD, L181 and D236. Thus,
mutagenized UbiA amino acids that resulted in loss of function
aligned to UBIAD1 residues mutated in SCD. This is a second
piece of evidence that a SCD mutation may lead to loss of function
of UBIAD1.
Modeling of UBIAD1 substrate docking indicates critical roles
for several residues mutated in SCD by suggesting a mutation of
these residues would block critical steps in catalysis. For example,
naphthalin-1,4-diol was docked as a speculative second substrate
of UBIAD1 and fitted nicely into the binding pocket (Figure S2).
However, a SCD mutation, N102S, changed binding of this
substrate completely, rendering its prenylation at position 3
impossible (Figure 6D and 6E). Although detailed modeling of
active site residues is full of uncertainty, this approach is supported
by modeling of UbiA that predicted the loss of enzyme activity and
was experimentally verified [16]. Further, modeling of UbiA was
able to connect the decreases in enzyme activity to specific
chemical functions of mutated residues, i.e. activation of a
Figure 4. Cellular localization of wild type human UBIAD1. Co-
localization within cultured normal human keratocytes of UBIAD1
protein and protein disulfide isomerase, an enzyme in endoplasmic
reticulum, is shown in panels A–C. Co-localization of UBIAD1 and
OXPHOS complex I, an enzyme in mitochondria, is shown in D–F.
UBIAD1 labeling is red (B and E). Protein disulfide isomerase and
OXPHOS I are green (A and D). UBIAD1 did not co-localize with the
endoplasmic reticulum (C), but did co-localize with mitochondria (co-
localizing red and green show as orange in F). Bar is 50 mm and applies
to all.
doi:10.1371/journal.pone.0010760.g004
Figure 5. Localization of SCD mutant UBIAD1. Co-localization of
UBIAD1 and OXPHOS complex I mitochondrial marker in keratocytes
derived from the Family KK proband (N102S mutation, panels A–C) and
a healthy donor (D–F). UBIAD1 (red, A and D) and a mitochondrial
marker (green, B and E) show co-localization (orange) in both normal (F)
and SCD disease keratocytes (C). Bar is 25 mm and applies to all.
doi:10.1371/journal.pone.0010760.g005
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mutation D236 in the UBIAD1 protein. This provides a third
indication that a mutation of UBIAD1 in SCD may be due to a
loss of function of the protein/enzyme.
The result that UBIAD1 did not localize with a marker for
endoplasmic reticulum (Figure 4) while wild type and N102S
mutant UBIAD1 did co-localize with a mitochondrial marker,
OXPHOS complex (Figure 4F), demonstrates that mislocalization
of N102S mutant protein is not a factor in SCD. Mitochondrial
localization is surprising in light of a previous report demonstrat-
ing interaction between UBIAD1 (also known as TERE1) and
apolipoprotein E [21,22]. To our knowledge, a mitochondrial
localization for apolipoprotein E has not been reported. However,
some UBIAD1 immunostaining was localized outside of mito-
chondria in these analyses making interaction with apolipoprotein
E outside of mitochondria possible.
SCD has been associated with deregulation of cholesterol
metabolism in the cornea as well as systemic hypercholesterolemia
[3]. The UBIAD1 gene had been shown to be expressed in B-cells
[20], however we found no significant differences in levels of
cholesterol metabolites in extracts of B-cell lines established from
SCD patients compared to an unaffected family member and
healthy donors (Table 2). This may indicate that UBIAD1 has a
specialized corneal function, perhaps relying on specific protein-
protein interactions (such as with apolipoprotein E) or in post-
translational modification of binding partners, perhaps with a
cholesterol or cholesterol-like moiety [23]. In this regards,
substrate docking simulations indicated that menaquinone fits
well into the interior of UBIAD1 (Figure 6F). This may be
significant since a relationship between menaquinone and
cholesterol metabolism has been suggested by prior publications
[24].
Experiments to determine if UBIAD1 will accept oligoprenyl
diphosphates as a substrate or ligand may be informative, but the
3D protein model clearly shows an optimal binding pocket for this
type of compound (Figure 6B and 6C). UBIAD1 may be an
aromatic prenyl transferase as indicated by its closest known
protein homologues. If so, a second substrate or ligand moiety may
be involved in enzyme catalysis, e.g. 4-hydroxy benzoate or a 1,4-
dihydroxy-naphthaline derivative.
The high degree of conservation of the protein across species,
and particularly residues mutated in SCD, indicates that the
protein may have an essential or at least ancient metabolic
function. These function(s) may play a role outside the cornea as
the gene is widely expressed in human tissues [20] and the protein is
present in species without eyes such as the sea urchin (Figure 2).
Modeling of UBIAD1 indicates the possibility of aromatic
prenylation as an enzyme activity. This biochemistry may
evolutionarily be at least as old as aerobic life, and it has been
described in human metabolism. Accordingly, UBIAD1 may have a
common origin directly from E. coli UbiA, but may not necessarily
act as a transferase (see Figure S1).
Presently, the only treatment for SCD is corneal replacement by
penetrating keratoplasty (PKP) once corneal opacification causes
decreased vision. PKP is performed in the majority of patients
above the age of 50 years with SCD [5]. Unfortunately, there are
no current therapies to prevent the progressive lipid deposition in
the cornea which results in this visual loss.
Prior studies have demonstrated that normalizing blood
cholesterol levels does not affect the relentless deposition of
corneal lipid that occurs with age [25]. Hopefully further
understanding about the impact of UBIAD1 gene mutations in
SCD will potentially lead to interventional strategies to prevent the
relentless accumulation of corneal lipid which results in visual loss
in these patients. Our results suggest that UBIAD1 protein
function is lost or decreased by SCD mutations. Thus, therapeutic
analogs of substrates which were successfully docked to the
UBIAD1 model (Figure S4) may further inhibit rather than restore
protein function. Examination of protein binding partners may
allow useful therapeutic targets to be identified.
Materials and Methods
Patients and Samples
New patients were recruited as previously described under
Institutional Review Board approval of University of Massachu-
Table 2. Analysis of Cholesterol in SCD and Healthy Patients.
Patient B cell SCD status TC (nmol/mg pr.)
a UC (nmol/mg pr.)
b CE (nmol/mg pr.)
c Ester/Total (%)
line ID AVE ± SD AVE ± SD AVE ± SD AVE ± SD
66K00597 unaffected control 44.0 ± 8.1 44.5 ± 8.7 20.6 6 2.2 21.2 6 4.5
BUC692RDP692A
66K00594 unaffected control 51.7 ± 8.4 49.9 6 8.6 1.8 6 0.2 3.5 6 0.9
BUC704RDP704A
66K00595 unaffected control 57.5 ± 0.3 55.1 6 0.8 2.4 6 1.0 4.2 6 1.8
BUC708RDP708A
64101374 affected proband 44.1 6 0.7 42.2 6 1.3 1.8 6 0.6 4.2 6 1.4
SCD Family AA
64101375 unaffected sibling 46.9 ± 2.3 45.9 6 2.2 1.0 6 0.2 2.2 6 0.4
SCD Family AA
64101376 affected proband 51.1 ± 1.5 49.6 6 1.2 1.5 6 0.3 3.0 6 0.5
SCD Family GG
aTC: total cholesterol.
bUC: unesterified cholesterol.
cCE: cholesteryl ester.
doi:10.1371/journal.pone.0010760.t002
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Medicine [5]. IRB approval was also obtained from the NIH
Office of Human Subjects Research. Creation of cell lines and
analysis of patient samples described in this study are covered by
the IRB approved protocol. All adults and parents of minors who
participated in the study provided written informed consent under
the research tenets of the Declaration of Helsinki. Affected
probands were recruited from other physicians and also were self
recruited by internet contact with JSW. Family history, ophthal-
mologic examination, blood samples were obtained on all affected
patients. When possible, other family members were recruited to
confirm the inherited nature of the SCD mutations. Ophthalmo-
logic examination included assessment of visual acuity and slit
lamp examination of the cornea detailing location and character-
istics of the corneal opacity. Notation was made as to the presence
of central corneal opacity, mid peripheral haze, arcus lipoides and
corneal crystalline deposition. Slit lamp photographs were
obtained whenever possible to document the diagnosis.
DNA Extraction and Sequencing
DNA was extracted using standard methods and either
Puregene (Gentra/Qiagen, Valencia, CA) or other Qiagen
reagents (All Prep DNA/RNA Kit). Genetic analysis of patient
DNA was performed as previously described, [8–10] except that
FastStart PCR reagents (Roche, South San Francisco, CA) and
ABI (Foster City, CA) thermal cyclers were used. Sanger
sequencing was performed using Big Dye reagents (ABI) and
subjected to chromatography using a 3730 Genetic Analyzer
(ABI). Sequence chromatograms were analyzed using Sequencher,
v4.8 (GeneCodes, Ann Arbor, MI). Over 100 control DNAs from
healthy donors were examined by double stranded sequencing for
each mutation to insure that mutations were novel, associated with
SCD, and unlikely to be rare polymorphisms. Healthy DNA
samples were obtained from the Dean Lab database (MD) and the
Coriell Institute for Medical Research (Camden, NJ).
Homology and Phylogeny
The following UBIAD1 sequences from 19 indicated species
were identified using the Ensembl database: NP_037451.1 [Homo
sapiens, human], XP_001137312.1 Predicted [Pan troglodytes,
chimp], XP_544571.1 Predicted [Canis familiaris, canine],
XP_585287.3 Predicted [Bos taurus, cattle], XP_001492378.1
Predicted [Equus caballus, horse], NP_082149.1 [Mus musculus,
mouse], XP_233672.1 Predicted [Rattus norvegicus, rat],
Figure 6. Three dimensional modeling of human UBIAD1. (A) Alignment of E.coli UbiA and human UBIAD1 with predicted transmembrane
helices (pred, bold italics), H=helix, I=inside, o=outside. Organic diphosphate binding residies are underlined. (B) Rainbow representation (side
view) of a putative 3D-structure of UBIAD1 in the membrane. Approximate location of the lipid bilayer is indicated (horizontal lines). Inside and
outside are arbitrary labels of membrane sidedness. Green spheres represent magnesium cations in the active site with a docked farnesyl-
diphosphate (red stick representation). The side chain of N102 is shown as a space-filled atom. (C) Top view as described in Fig. 6B. Magenta atoms
show potential binding of a putative substrate. (D) Hypothetical docking of farnesyldiphosphate and a 1,4-dihydroxy aryl compound. Substrate
recognition by N102 (arrow) and R235 via hydrogen bonds and by hydrophobic interactions with P64 are indicated (dashed lines). The distance of the
C2-atom of the hydroquinone to the C1-atom of the farnesyl moiety is 3.8 A ˚ (red dashed line). (E) Docking arrangement of the two putative
substrates as in Figure 6D upon in silico mutation of UBIAD1 from asparagine 102 to serine (arrow). The aromatic substrate is no longer recognized by
N102, but by S69 and, as before, by R235 and P64. C2 of the aromatic substrate is no longer positioned correctly to allow prenylation. (F) Active site of
UBIAD1 with a menaquinone-farnesyl derivative that optimally docks to the protein. Substrates with longer fatty acid tails were also successfully
docked. The interaction is stabilized by hydrogen bonds (dashed lines) with N102 and R235. R235 may be influenced by neighboring residues, N232,
N233, and D236, which cause SCD when altered. The quinone moiety and farnesyl chain are recognized by P64, F107, and other indicated residues via
hydrophobic interactions.
doi:10.1371/journal.pone.0010760.g006
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[Danio rerio, zebrafish], ENSORLT00000000192 Predicted
[Oryzias latipes, medaka/killifish], NP_523581.1 [Drosophila melano-
gaster, fruitfly], XP_001639930.1 Predicted [Nematostella vectensis,
sea anemone], XP_001175897.1 Predicted [Strongylocentrotus pur-
puratus, sea urchin], ENSCPOG00000011678 Predicted [Cavia
porcellus, Guinea pig], ENSFCAG00000000057 Predicted [Felis
catus, cat], ENSLAFG00000015673 Predicted [Loxodonta Africana,
African elephant], ENSPCAG00000003043 Predicted [Procavia
capensis, hyrax], ENSMODG00000011080 Predicted [Monodelphis
domestica, opposum], ENSTTRG00000001324 Predicted [Tursiops
truncates, bottlenose dolphin], ENSPVAG00000014788 Predicted
[Pteropus vampyrus, megabat/flying fox]. Alignments were per-
formed using Clustal 2.0.11 [15]. A global alignment performed
on all proteins was followed by local optimization of overlapping,
sequential regions of protein in approximately fifty amino acid
increments.
Localization of Human UBIAD1
Normal human keratocytes were purchased from ScienCell
Research Lab (Carlsbad, CA). Schnyder corneal dystrophy and
normal human keratocytes were cultured at 37uC in Fibroblast
Medium (catalogue no. 2301) also obtained from ScienCell
Research Lab. For immunofluorescence labeling experiments,
the keratocytes were rinsed three times with DPBS before fixing
with 2% formaldehyde for 10 minutes at room temperature. Cells
were then blocked with 10% FBS in DPBS (FBS blocking solution)
for 30 minutes, and then treated 15 minutes with avidin/biotin
blocker (Vector Laboratories, Burlingame, CA) with a DPBS rinse
between each step of the procedure described by the manufactur-
er. Chicken anti-UBIAD1 was diluted to 5 mg/ml in FBS blocking
solution containing 0.2% Triton X-100, and incubated with
keratocytes for one hour at room temperature. After three five-
minute rinses with DPBS, biotinylated goat anti-chicken IgY
(catalogue no. 103-065-155 from Jackson Immunoresearch, West
Grove, PA) diluted to 5 mg/ml in FBS blocking solution was
incubated with keratocytes for one hour. This primary labeling of
UBIAD1 protein was then visualized by incubating keratocytes
with 5 mg/ml Alexa 594 (red) streptavidin diluted in DPBS
(catalog no. S32356, Molecular Probes, Eugene, Oregon).
To determine the subcellular localization of UBIAD1, kerato-
cytes were further incubated one hour with either 5 mg/ml mouse
IgG2b monoclonal anti-protein disulfide isomerase (catalogue
no. S34253, Molecular Probes), an endoplasmic reticulum marker;
or 5 mg/ml mouse IgG1 monoclonal anti-OXPHOS Complex I
subunit, NADH dehydrogenase (catalogue no. A31857, Molecular
Probes), a mitochondrial marker. This was followed by incubation
with 5 mg/ml Alexa fluor 488 (green) anti-mouse IgG (catalogue
no. A11029, Molecular Probes) for one hour to label the
subcellular markers. All antibodies were diluted in FBS blocking
solution.
Cholesterol Measurements
Lymphocytes were isolated from patient blood samples using
lymphocyte separation medium and were immortalized using
Epstein-Barr virus. Standard culture conditions utilized RPMI
1640 media (Invitrogen), 15% fetal bovine serum (Hyclone,
Waltham, MA), and 26L-glutamine (Invitrogen). Six well plates
were used to grow approximately 1 million cells per well, which
were rinsed three times each with Dulbecco’s phosphate-buffered
saline (DPBS) plus Mg
2+,C a
2+, and 0.2% bovine serum albumin
(BSA), and then DPBS plus Mg
2+ and Ca
2+. Cells were harvested
from wells by scraping into 1 ml of distilled water, and then
processed as described previously [26]. Lipids were extracted from
an aliquot of cell suspension using the Folch method [27]. The
cholesterol content of cells was determined according to the
fluorometric method of Gamble et al. [28]. Protein content was
determined on another aliquot of cell suspension by the method of
Lowry et al. using BSA as a standard [29].
Figure 7. Locations of selected SCD alterations. (A) Sideview of UBIAD1 showing locations of wild type amino acids mutated in SCD. (B) Top
view as in Figure 7A. In each view, only several residues mutated in SCD are visible. Farnesyldiphosphate is shown as a stick representation. The
sidechains of SCD mutations reported in this paper are shown as spacefilled atoms: A97, N102, D112, V122, and L188.
doi:10.1371/journal.pone.0010760.g007
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UBIAD1 transmembrane helices and topology were analyzed
using the HMMTOP program and server [30,31] The Brookha-
ven Protein Data Bank (PDB) and PHYRE (Protein Homology/
analogYR ecognition Engine) were searched for proteins homol-
ogous to UBIAD1 using BLASTp [31]. Homology between
UBIAD1 and other prenyltransferases was examined using MOE
(Molecular Operating Environment, Chemical Computing Group
Inc., Montreal, Canada). Transmembrane helices were manually
examined by using available X-ray structures of prenyl converting
enzymes as templates, such as prenyl synthases (cyclases), protein
prenyl transferases, and the recently developed model of the all-
alpha-helical E. coli UbiA prenyltransferase [16,17]. Alignment
was performed as previously described [16]. The positional
placement of geranylpyrophosphate and a single magnesium
cation were extracted from the E. coli UbiA model. The model
obtained from MOE was refined using the molecular dynamics
refinement tool YASARA and stereochemical quality was
analyzed with PROCHECK [32]. All parameters evaluated were
better (overall G-factor) then required for an analogous X-ray of
better than 2 A ˚ resolution. Inspection of the fold quality was done
with ERRAT [33].
Substrate suitability was approached by examining homologous
proteins in the Uniprot Knowledgebase Release 15.2 database.
Substrates examined are available upon request. Substrate binding
and dynamics (4-hydroxybenzoic acid and 1, 4-naphthalin-diol)
were evaluated using automated docking and molecular dynamics
simulations (GOLD [34]).
Web Resources
The URLs for data presented herein are as follows: Online
Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.
nih.gov/OMIM/; Entrez Nucleotide, http://www.ncbi.nlm.nih.
gov/nuccore; Ensembl, http://www.ensembl.org/index.html;
HMMTOP, http://www.enzim.hu/hmmtop/index.html; PHYRE,
http://www.sbg.bio.ic.ac.uk/,phyre; RCSB Protein Data Bank,
http://www.rcsb.org/pdb/home/home.do; BLASTp, http://blast.
ncbi.nlm.nih.gov/Blast.cgi; Molecular Operating Environment,
http://www.chemcomp.com; YASARA, http://www.yasara.org;
PROCHECK, http://www.biochem.ucl.ac.uk/,roman/procheck/
procheck.html; ERRAT, http://nihserver.mbi.ucla.edu/ERRATv2/;
UniProt knowledge base, http://www.expasy.ch/sprot/; TOPO2,
http://www.sacs.ucsf.edu/TOPO2/.
Supporting Information
Figure S1 Key enzymatic prenylation reaction catalyzed by
UbiA during biosynthesis of ubiquinone [16,17]. Prenylation of 4-
hydroxybenzoic acid by oligoprenyl diphosphates are shown
(n.1). A two substrate reaction is shown similar to that proposed
for human UBIAD1 (see Discussion).
Found at: doi:10.1371/journal.pone.0010760.s001 (1.19 MB TIF)
Figure S2 Docking simulation with naphthalinediol as a putative
substrate. Tertiary protein structure model of human UBIAD1
with eight transmembrane helices and a putative naphthalinediol
substrate docked (shown as a spacefill atom representation).
Found at: doi:10.1371/journal.pone.0010760.s002 (2.99 MB TIF)
Figure S3 Models showing locations of Loops 1–3 containing
clusters of SCD mutations. See also Figure 3B for comparison, to
identify SCD mutations in each loop. Two views are shown, a side
view (left side) and top view (right side). These highlight the loop
regions containing amino acids implicated in SCD. Loop 1
(containing amino acids A97 to R132) is shown in orange, loop 2
(Y174 to A184) in blue, and loop 3 (L229 to S257) in green.
Mutated S102 is shown as a spacefill atom and a docked
farnesyldiphosphate is shown as a stick representation (red).
Found at: doi:10.1371/journal.pone.0010760.s003 (6.59 MB TIF)
Figure S4 Structures of potential substrates successfully
docked with the UBIAD1 model. (A) Farneslydiphosphate
(C15H25O7P2-3). (B) Menaquinone (C11H8O2). (C) Naphthale-
nediol (C10H8O2).
Found at: doi:10.1371/journal.pone.0010760.s004 (0.93 MB TIF)
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